Table 2.

Response from ponatinib treatment: Phase I trial data

	Chronic phase CML (n = 43)		Accelerated phase CML, blast phase CML, and Ph+ ALL (n = 22)
	All patients (n = 43)	T3151 mutation (n = 12)	All patients (n = 22)	T3151 mutation (n = 7)
CCyR	27 (63%)	9 (75%)	3 (14%)	1 (14%)
MCyR	31 (72%)	11 (92%)	7 (32%)	2 (29%)
CHR	42 (98%)	12 (100%)	N/A	N/A
MaHR	N/A	N/A	8 (36%)	2 (29%)
MMR	19 (44%)	8 (67%)	2 (9%)	2 (29%)

Abbreviations: CCyR, complete cytogenetic response; CHR, complete hematologic response; CML, chronic myeloid leukemia; MaHR, major hematologic response; MCyR, major cytogenetic response; MMR, major molecular response; N/A, not available; Ph+ ALL, Philadelphia chromosome positive acute lymphoblastic leukemia.